Peptides for Anti-Aging Research
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
This guide provides a comprehensive overview of two peptides currently under investigation for their potential anti-aging effects. These compounds are evaluated based on the strength of available evidence, ranging from FDA-approved therapies to those explored primarily in early preclinical stages. The analysis encompasses their mechanisms of action, clinical status, and safety profiles, allowing for a clearer understanding of their roles in anti-aging research.
Overview
2 research peptides are currently studied for anti-aging research. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Pinealon — Preclinical / Uncontrolled Russian Studies
Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide with a molecular weight of approximately 418 g/mol, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. This compound is classified as a bioregulatory peptide, primarily targeting the brain and pineal gland functions. Research is predominantly limited to preclinical studies and small-scale open-label clinical observations conducted in Russia, lacking rigorous controlled trials published in peer-reviewed international journals. Notably, studies suggest that Pinealon may exhibit neuroprotective properties in cell culture models and potentially enhance melatonin production, which could have implications for sleep regulation and circadian rhythms. However, the absence of larger, controlled studies raises questions about the reproducibility and generalizability of these findings, warranting caution in interpreting its potential benefits.
Cortagen — Preclinical / Uncontrolled Russian Studies
Cortagen (Ala-Glu-Asp-Leu, AEDL) is a synthetic tetrapeptide with a molecular weight of around 446 g/mol, also developed by Vladimir Khavinson as a bioregulatory peptide aimed at modulating functions within the cerebral cortex. Similar to Pinealon, the evidence supporting Cortagen is primarily derived from Russian preclinical studies and small, uncontrolled clinical observations, with no independent replications or controlled trials documented in the broader scientific literature. Preliminary findings indicate that Cortagen may confer neuroprotective effects in ischemia models and has been suggested to normalize gene expression in cortical tissue. While these claims are intriguing, the limited scope and methodological rigor of existing studies highlight the need for further investigation to validate these effects and understand their implications for anti-aging therapies.
Shop Research Peptides
Cagrilintide 5mg
DSIP 10mg
Epithalon 10mg
GHRP-2 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Pinealon (EDR) Tripeptide: Research Guide for 2026
Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide from the Khavinson bioregulator program. This guide reviews the published evidence on its nuclear DNA binding, neuroprotective effects in cell culture and animal models, and the limits of the current research base.
Pinealon: Neuroprotective Tripeptide Research Guide
Pinealon, a synthetic tripeptide known as Glu-Asp-Arg or EDR, targets the central nervous system for neuroprotection. Developed by Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology, it shows effects on gene expression, cell proliferation, and protection against oxidative stress in neuronal models. Studies highlight reduced apoptosis, preserved mitochondrial function, and potential benefits in hypoxia and aging contexts, though much data comes from one research group.
Zepbound: A Research Perspective on Cognitive Peptides and Focus
Zepbound is a term associated with research into cognitive peptides and nootropic compounds. This article explores the preclinical evidence behind peptides like Semax, Selank, and Pinealon, which are studied for their effects on BDNF expression, neuroprotection, and synaptic plasticity. Learn how Volta Peptides supports researchers with verified compounds and tools for reliable experimentation.
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Frequently Asked Questions
Related Resources
Related Research
About the reviewer

Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.








